Bolt Biotherapeutics Stock Market Outlook
| BOLT Stock | USD 4.67 0.08 1.74% |
Earnings surprises, macro shifts, and narrative changes can each leave a measurable footprint in the score, which is why sentiment is treated as context rather than proof on its own. Around 58% of recent sentiment around Bolt Biotherapeutics has been slightly more constructive than defensive over the recent sample. Taken on its own, that leaves the current sentiment reading for Bolt Biotherapeutics slightly above neutral right now.
Investor Comfort Level
PanicConfidence
58 · Interested
Elasticity to Hype and News Sentiment
At 14%, Bolt Biotherapeutics news tone is negative, providing a perception layer that can precede fundamental repricing. Comparing perception data with actual financial results can separate headline-driven pressure from genuine fundamental change.
Given a 90-day horizon, with an above-average risk tolerance, the model output for Bolt Biotherapeutics is 'Strong Sell'. The recommendation model incorporates Bolt Biotherapeutics' available fundamental, technical, and predictive indicators.
Bolt |
Run Bolt Biotherapeutics Outlook Model
This Bolt module delivers a quantitative summary that supplements analyst views on Bolt Biotherapeutics. Macroaxis has no ownership or residual interests in Bolt Biotherapeutics or other analyzed instruments. The Bolt Biotherapeutics' output adapts to changes in volatility, momentum, and fundamental signals. A balanced approach combines this algorithmic output with broader market research.
How This Model Works
The recommendation output for Bolt Biotherapeutics is a model-based view that converts the selected horizon and risk profile into a standardized reading of the current evidence.
- Inputs - valuation signals, price behavior, volatility, liquidity, sentiment, and analyst coverage when available
- Current setup - Three Months with a risk setting described as I am an educated risk taker
- Limits - the model does not account for taxes, outside holdings, concentration constraints, or investor-specific mandates
Use the output as structured decision support and pair it with your own research, portfolio context, and any professional advice you rely on.
Time Horizon
Risk Tolerance
Strong Sell
Market Performance | Weak | Details | |
Volatility | Slightly Elevated | Details | |
Current Valuation | Below Model Estimate | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Moves slightly opposite to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Bolt Biotherapeutics' current outlook reflects a cautious setup, where weak recent performance and soft fundamental readings cloud near-term visibility, while risk metrics have not deteriorated further. The model's 'Strong Sell' signal reflects persistent headwinds that outweigh the offsetting factors in the model. Over the selected time horizon, Bolt Biotherapeutics shows Mean Deviation of 3.99, Standard Deviation of 5.31, and Variance of 28.24, which weigh on the current risk-reward outlook.The model output for Bolt Biotherapeutics integrates risk-adjusted performance, valuation signals, and the current analyst and expert consensus into a single quantitative reading. For additional context on this micro-cap stock in the Health Care sector, examine the full set of Bolt Biotherapeutics reported fundamentals, including the relationship between the net income ttm and target price. Bolt Biotherapeutics has a price to earnings ttm of 36.55 X. Its market performance and bankruptcy risk for the current cycle warrant close attention.
Recent Events and Market Context
The events below reflect recent headlines associated with Bolt Biotherapeutics. Not all items directly affect the outlook — they are included to show the broader information environment that can shape sentiment and trading behavior.
Current Analysts Advice
Consensus analysis around Bolt Biotherapeutics is designed to show how professional opinion is clustering as the market re-evaluates growth, valuation, and operating execution within the Health Care sector. Rating changes are most informative when they start to diverge from price action or the underlying business trend.
Average Consensus Buy
The consensus target-price view on Bolt Biotherapeutics is an average of outside analyst opinions and should not be assumed to match Macroaxis advisory output. With a current consensus of Buy across 4 analysts, in practice, this is a market-sentiment reference point rather than a complete investment thesis.
Returns Distribution Density
This distribution maps every daily return Bolt Biotherapeutics has posted. Most days cluster near the average return, and the further from the mean, the rarer those moves become. Value At Risk and Upside Potential sit at opposite ends, showing the worst and best likely outcomes. Value At Risk and Upside Potential serve as the key markers for downside and upside.
| Mean Return | -0.11 | Value At Risk | -7.91 | Potential Upside | 9.85 | Standard Deviation | 5.31 |
Return Density |
| Distribution |
Understanding Bolt Biotherapeutics's risk starts with seeing how often large price swings happen. The historical return chart puts hard numbers on that question. This enables comparison of risk-return profiles with a clear picture of the downside. The chart frames the trade-offs that matter most in the context of analysis of Bolt Biotherapeutics exposure.
Top Institutional Investors
Annual revenue is about 7.7 million. How Bolt Biotherapeutics's institutional base reacts to earnings changes can move the stock in the short term. Shares outstanding are near 1.92 million. Whether the institutional base is growing or shrinking quarter over quarter matters more than the current snapshot.
| Shares | Vanguard Group Inc | 2025-12-31 | 10.2 K | Blackrock Inc | 2025-12-31 | 9.7 K | Morgan Stanley - Brokerage Accounts | 2025-12-31 | 3.1 K | Tower Research Capital Llc | 2025-12-31 | 723 | Citigroup Inc | 2025-12-31 | 256 | Jpmorgan Chase & Co | 2025-12-31 | 42.0 | Bank Of America Corp | 2025-12-31 | 31.0 | Sbi Securities Co Ltd | 2025-12-31 | 10.0 | Barclays Plc | 2025-12-31 | 6.0 | Sofinnova Ventures | 2025-12-31 | 137.7 K | Pivotal Bioventure Partners Investment Advisor Llc | 2025-12-31 | 94.6 K |
Cash Flow Accounts
| 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Other Cashflows From Investing Activities | -229.9M | 59.8M | 148K | 963K | 1.0M |
Key Drivers of Volatility and Market Exposure
Bolt Biotherapeutics combines broad market sensitivity with company or sector-specific developments. Diversification may lower asset-specific risk, but systematic volatility remains inherent. Bolt Biotherapeutics reported a Mean Deviation of 3.99 and a Standard Deviation of 5.31.
α | Alpha over Dow Jones | -0.1299 | |
β | Beta against Dow Jones | -0.5947 | |
σ | Overall volatility | 5.20 | |
Ir | Information ratio | -0.0177 |
Fundamentals Vs Peers
Bolt Biotherapeutics' valuation multiples, profitability ratios, and leverage metrics are benchmarked below against comparable stocks. When Bolt Biotherapeutics outperforms peers on profitability or returns while trading at a discount, the gap warrants investigation. Bolt Biotherapeutics's capital efficiency, margin trajectory, and leverage profile are each compared to the peer median. Bolt Biotherapeutics' financial profile relative to comparable stocks frames the discussion of whether current pricing is justified.
| Better Than Average | Worse Than Average | Compare Bolt Biotherapeutics to competition |
Note: Acquisition by Grant Yonehiro of 11749 shares of Bolt Biotherapeutics at 5.44 subject to Rule 16 b-3 [view details]
Market Momentum
Beta of -0.5947 dampens broad market moves. Market-strength indicators for Bolt Biotherapeutics help investors judge how the stock is reacting to changing momentum conditions. For Bolt Biotherapeutics, these strength readings pair best with earnings momentum and volume confirmation.
Recommendation Framework, Assumptions & Editorial Oversight
The model output for Bolt Biotherapeutics reflects the current horizon and risk settings, refreshes as underlying data changes, and is intended to organize evidence rather than replace investor judgment. Current model inputs for Bolt Biotherapeutics include P/E of 36.55, ROE of -79.75%. External analyst coverage is currently summarized as Buy across 4 analysts, but it is treated here as a secondary reference input rather than a stand-alone recommendation. Published target-price assumptions may also be reviewed when available, but they can change quickly as analyst models are revised. 
Bolt Biotherapeutics data is compiled from periodic company reporting and market reference feeds and standardized for comparability. The model combines valuation, price behavior, volatility, and sentiment into a standardized quantitative view.
Editorial Review & Methodology Oversight
Role: Member of Macroaxis Editorial Board
Finance background: Gabriel is a young entrepreneur and writes predominantly on the business, technology, and finance sector. He likes to analyze different equity instruments across a wide range of industries focusing primarily on consumer products and evolving technologies.
Oversight scope: Reviews recommendation-framework framing, source assumptions, and disclosure language.